LAVA Therapeutics (NASDAQ:LVTX) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report report published on Thursday morning, Marketbeat Ratings reports. They currently have a $1.50 target price on the stock, down from their previous target price of $2.00.

Several other analysts have also commented on LVTX. Leerink Partners restated a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Stock Performance

LAVA Therapeutics stock opened at $1.29 on Thursday. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $6.47. The company has a market capitalization of $33.91 million, a PE ratio of -1.25 and a beta of 0.57. The company has a 50 day moving average price of $0.99 and a 200-day moving average price of $1.44.

LAVA Therapeutics (NASDAQ:LVTX) last posted its earnings results on Tuesday, December 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). On average, analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Institutional Investors Weigh In On LAVA Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in LAVA Therapeutics in the 3rd quarter valued at approximately $32,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics in the fourth quarter valued at $40,000. Finally, Sanofi purchased a new stake in shares of LAVA Therapeutics in the 4th quarter valued at $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.